Sepsis Diagnostic Market by Testing Type (Laboratory Testing, PoC Testing), Technology (Flow Cytometry, Immunoassays, Microbiology), Product, Method, Pathogen, End-user - Global Forecast 2024-2030

Sepsis Diagnostic Market by Testing Type (Laboratory Testing, PoC Testing), Technology (Flow Cytometry, Immunoassays, Microbiology), Product, Method, Pathogen, End-user - Global Forecast 2024-2030

The Sepsis Diagnostic Market size was estimated at USD 556.86 million in 2023 and expected to reach USD 611.80 million in 2024, at a CAGR 9.98% to reach USD 1,084.17 million by 2030.

Sepsis diagnostics refers to the variety of procedures and tests used to identify and confirm the presence of sepsis in patients. Sepsis is a condition that arises from the body's reaction to an infection that causes injury to its tissues and organs; thus, sepsis diagnostics are essential for the timely and accurate detection of sepsis, leading to immediate and appropriate treatment interventions. There is an increasing need for sepsis diagnostics, as they are critical in saving lives, preventing disease progression, reducing healthcare costs, and enhancing the quality of life for patients impacted by sepsis. The growing number of sepsis cases globally due to rising infection rates, aging populations, and higher susceptibility in individuals with chronic diseases has led to an increasing need for efficient diagnostic methods. Improved healthcare infrastructure, particularly in developing countries, along with better healthcare policies and increased healthcare spending, supports the growth of the sepsis diagnostic market. However, the lack of awareness and understanding of sepsis in several underdeveloped regions limits the need for diagnostic solutions. Nevertheless, advances in technology that offer the potential to reduce diagnosis time and improve patient outcomes are expected to create opportunities for the adoption of sepsis diagnostics solutions.

Regional Insights

In the Americas, particularly in North America, the sepsis diagnostics market is witnessing significant growth, growing healthcare facilities, heightened awareness about sepsis, and substantial investment in research and diagnostic technologies. South America is seeing improvements in healthcare access and an increasing emphasis on early diagnosis and treatment, driving the need for sepsis diagnostics. Asia-Pacific region represents an emerging sepsis diagnostics market, propelled by its large population, elevating healthcare expenditure, and growing awareness of sepsis as a critical health issue. Countries in the Asia-Pacific are benefiting from governmental healthcare reforms and investments in healthcare infrastructure, causing a significant adoption of advanced sepsis diagnostics solutions. The Europe, Middle East, and Africa region presents a varied landscape for the sepsis diagnostics market. Europe noticed strong growth driven by well-established healthcare systems, high healthcare spending, and stringent regulatory standards promoting the adoption of advanced diagnostics.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Sepsis Diagnostic Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing Incidence and Prevalence of Sepsis
• Growing Occurrence of Hospital Derived Infections
• Development of Technology Advanced Diagnostic Solutions

Market Restraints

• Capital Intensive Automated Diagnostic Services and Dearth of Reimbursement Situations

Market Opportunities

• Emerging Development of Rapid Diagnostics Globally
• Development of Novel Biomarkers for Sepsis Diagnostics

Market Challenges

• Lack of Awareness and Standard Protocols for the Procedure

Market Segmentation Analysis

• Testing Type: Increasing usage of PoC testing solutions for sepsis diagnostics
• End-user: Emerging use of advanced sepsis diagnostics solutions in pathology and reference laboratories

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Sepsis Diagnostic Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Sepsis Diagnostic Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Unveiling of FDA-Authorized AI Tool by Prenosis, Inc.

Prenosis, Inc. achieves a monumental milestone with the FDA’s marketing authorization of the Sepsis ImmunoScore, marking the debut of an AI-driven diagnostic tool for sepsis. With this FDA authorization, Prenosis underscores its dedication to transforming acute care through precision medicine, heralding a new era in personalized healthcare solutions driven by AI diagnostics.

Innovative AI-Powered Early Detection of Sepsis by Presymptom Health Secures GBP 1.5 Million in Funding

Presymptom Health secured GBP 1.5 million in a combination of equity and grant funding, reflecting the potential of its AI and machine learning technologies to revolutionize early infection detection. Leveraging vast biobank data, Presymptom Health's advanced analytics can identify signs of infections and sepsis significantly earlier than traditional methods, potentially days before clinical symptoms become apparent. This funding round, featuring contributions from UKI2S, Ploughshare, and MedTechToMarket along with Innovate UK grants, underscores AI's significant advances and the promise in healthcare, especially for conditions including sepsis that need swift intervention.

Cytovale's Strategic Advancement with USD 84 Million Series C Funding

Medical technology firm Cytovale made a stride in sepsis diagnosis with its innovative test, IntelliSep, through an USD 84 million Series C funding round. This funding aims to tackle the pressing issue of delayed sepsis diagnosis, which incurs an annual cost of USD 62 billion nationwide.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Sepsis Diagnostic Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Sepsis Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alifax S.r.l., Beckman Coulter, Inc., Becton, Dickinson and Company, bioMérieux SA, Boditech Med Inc., Bruker Corporation, CytoSorbents Corporation, DiaSorin S.p.A., EKF Diagnostics, F. Hoffmann-La Roche AG, Immunexpress Inc., Koninklijke Philips N.V., McKesson Corporation, Nanomix Inc., Oracle Corporation, Response Biomedical Corporation, Seegene Inc., Siemens Healthineers, T2 Biosystems, Thermo Fisher Scientific, Inc., and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the Sepsis Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

Testing Type

• Laboratory Testing
• PoC Testing
• Technology
• Flow Cytometry
• Immunoassays
• Microbiology
• Molecular Diagnostics
• Product
• Assay Kits and Reagents
• Blood Culture Media
• Instruments
• Software
• Method
• Automated Diagnostics
• Conventional Diagnostics
• Pathogen
• Bacterial Sepsis
• Gram-Negative Bacteria
• Gram-Positive Bacteria
• Fungal Sepsis
• End-user
• Hospitals
• Pathology & Reference Laboratories
• Research Laboratories & Academic Institutes

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year